Assetmark Inc. Purchases 2,510 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Assetmark Inc. boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 25.7% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 12,285 shares of the medical research company's stock after acquiring an additional 2,510 shares during the quarter. Assetmark Inc.'s holdings in Charles River Laboratories International were worth $1,849,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. Geode Capital Management LLC increased its stake in Charles River Laboratories International by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock worth $227,042,000 after buying an additional 14,787 shares in the last quarter. Ariel Investments LLC lifted its stake in Charles River Laboratories International by 18.9% during the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after purchasing an additional 169,640 shares in the last quarter. Invesco Ltd. lifted its stake in Charles River Laboratories International by 17.1% during the fourth quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock worth $190,910,000 after purchasing an additional 151,159 shares in the last quarter. Mackenzie Financial Corp raised its stake in shares of Charles River Laboratories International by 0.6% in the fourth quarter. Mackenzie Financial Corp now owns 977,073 shares of the medical research company's stock valued at $180,368,000 after acquiring an additional 5,805 shares in the last quarter. Finally, D1 Capital Partners L.P. acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $172,752,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Price Performance

Shares of Charles River Laboratories International stock traded down $2.75 on Friday, hitting $166.89. The company had a trading volume of 821,687 shares, compared to its average volume of 783,127. The business has a 50-day simple moving average of $153.56 and a 200-day simple moving average of $149.73. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The company has a market cap of $8.20 billion, a PE ratio of -256.75, a PEG ratio of 5.74 and a beta of 1.48. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $236.88.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter in the prior year, the firm earned $2.27 EPS. The firm's quarterly revenue was down 2.7% on a year-over-year basis. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on CRL. Robert W. Baird raised their price objective on Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. Mizuho reduced their price target on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Citigroup raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Finally, Redburn Atlantic raised shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price target for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $174.54.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president directly owned 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).